title: Multidrug-resistant tuberculosis in Uzbekistan: results of a nationwide survey, 2010 to 2011.
abstract: Multidrug-resistant tuberculosis (MDR-TB; resistance to at least rifampicin and isoniazid) is a global public health concern. In 2010–2011, Uzbekistan, in central Asia, conducted its first countrywide survey to determine the prevalence of MDR-TB among TB patients. The proportion of MDR-TB among new and previously treated TB patients throughout the country was measured and risk factors for MDR-TB explored. A total of 1,037 patients were included. MDR-TB was detected in 165 treatment-naïve (23.2%; 95% confidence interval (CI) 17.8%–29.5%) and 207 previously treated (62.0%; 95% CI: 52.5%–70.7%) patients. In 5.3% (95% CI: 3.1%–8.4%) of MDR-TB cases, resistance to fluoroquinolones and second-line injectable drugs (extensively drug resistant TB; XDR-TB) was detected. MDR-TB was significantly associated with age under 45 years (adjusted odds ratio: 2.24; 95% CI: 1.45–3.45), imprisonment (1.93; 95% CI: 1.01–3.70), previous treatment (4.45; 95% CI: 2.66–7.43), and not owning a home (1.79; 95% CI: 1.01–3.16). MDR-TB estimates for Uzbekistan are among the highest reported in former Soviet Union countries. Efforts to diagnose, treat and prevent spread of MDR-TB need scaling up.
authors.affiliation: Republican DOTS Centre, Tashkent, Uzbekistan.
authors.forename: D J
authors.initials: DJ
authors.lastname: Ulmasova
authors.forename: G
authors.initials: G
authors.lastname: Uzakova
authors.forename: M N
authors.initials: MN
authors.lastname: Tillyashayhov
authors.forename: L
authors.initials: L
authors.lastname: Turaev
authors.forename: W
authors.initials: W
authors.lastname: van Gemert
authors.forename: H
authors.initials: H
authors.lastname: Hoffmann
authors.forename: M
authors.initials: M
authors.lastname: Zignol
authors.forename: K
authors.initials: K
authors.lastname: Kremer
authors.forename: T
authors.initials: T
authors.lastname: Gombogaram
authors.forename: J
authors.initials: J
authors.lastname: Gadoev
authors.forename: P
authors.initials: P
authors.lastname: du Cros
authors.forename: N
authors.initials: N
authors.lastname: Muslimova
authors.forename: A
authors.initials: A
authors.lastname: Jalolov
authors.forename: A
authors.initials: A
authors.lastname: Dadu
authors.forename: P
authors.initials: P
authors.lastname: de Colombani
authors.forename: O
authors.initials: O
authors.lastname: Telnov
authors.forename: A
authors.initials: A
authors.lastname: Slizkiy
authors.forename: B
authors.initials: B
authors.lastname: Kholikulov
authors.forename: M
authors.initials: M
authors.lastname: Dara
authors.forename: D
authors.initials: D
authors.lastname: Falzon
mesh_terms: D000293:Adolescent; D000328:Adult; D000367:Age Factors; D000368:Aged; D000369:Aged, 80 and over; D000995:Antitubercular Agents / Q000494:pharmacology*; D002648:Child; D002675:Child, Preschool; D005260:Female; D006306:Health Surveys; D006801:Humans; D015994:Incidence; D008297:Male; D008826:Microbial Sensitivity Tests; D008875:Middle Aged; D009169:Mycobacterium tuberculosis / Q000187:drug effects* / Q000235:genetics / Q000302:isolation & purification*; D011159:Population Surveillance; D015995:Prevalence; D012307:Risk Factors; D013183:Sputum / Q000382:microbiology; D018088:Tuberculosis, Multidrug-Resistant / Q000188:drug therapy* / Q000453:epidemiology* / Q000382:microbiology; D014610:Uzbekistan / Q000453:epidemiology; D055815:Young Adult
chemical_list: D000995:Antitubercular Agents